Nyhet -

Circius Pharma is a “New” Swedish company with development in both medtech and pharma

The company is named after a powerful northern wind. Founder Jan G. Smith

appreciated the symbolism of being a northern firm and growing like a forceful northern wind.

Over 30 years ago, Jan G. Smith founded Abigo Medical, a successful company also known worldwide thanks to its unique wound care product Sorbact. Jan now transfers decades of knowledge to Circius Pharma, a family owned company, and is viewing the future with high expectations.

Both medtech and pharma

Circius Pharma is a young company, but it is based on decades of experience and contacts in the life science industry. In connection with having sold Abigo Medical, Jan G Smith last year acquired its pharma division, now active under the name Circius Pharma AB and wholly owned by Jan G.Smith.

The takeover includes all related products and the experienced staff. The company is located in Askim, Gothenburg.

“We thus have a “new” Swedish pharma company with long experience in both R&D, marketing and being internationally active. It is essentially the same road we travelled with Abigo, and I see it as a big advantage and a head start that we already have the experience from having done a similar trip before”, says Jan G. Smith.

Circius Pharma has now established subsidiaries in both Norway and Denmark, and thus covers the Scandinavian market. Apart from its existing products, both in medtech and in pharma, Circius also has an interesting product program under development.

Strong development environments

Apart from establishing and building up Abigo Medical, Jan G. Smith was also one of the initiators of the start and development of Sahlgrenska Science Park, at a time when there were no other similar development environments in the Gothenburg region.

“I believe in establishing and running strong development environments where innovations can grow”, says Jan, who was chairman of the board of Sahlgrenska Science Park for the first 13 years.

Furthermore, together with one of Germany’s largest pharmaceutical associations, Jan G. Smith was also instrumental in founding a successful European pharma association, Eucope, with office in Brussels. Eucope is today a strong voice promoting the interests of European life science companies. Jan G. Smith remains chairman of this active association from start-up 14 years ago.

All this creates an interesting large international network that benefits Circius Pharma. Jan G. Smith also owns and runs the parent company Gobia Enterprises, which invests in innovative and promising companies primarily in Life Science. Gobia has so far invested in 10 interesting Swedish life science companies.

What are the main success factors?

“During the first year, Circius Pharma will have a turnover of over SEK 100 million. This is thanks to an experienced staff and a well-established products portfolio. It is a good starting position for the company, which now is focused on expansion, internationally and in the Nordic countries. R&D is also a key word for Circius Pharma”.

Any thoughts on further growth?

“Circius Pharma will continue to grow at a brisk rate. We do not see the company as a start-up, even if it is newly founded. This is thanks to the history and all the competence we already have accumulated from our time at Abigo Medical”.

How about the parent company?

“For Gobia Enterprises, we have interesting investments. We invest long term and are not chasing the easy short-sighted buck. What we mainly look at is the company’s uniqueness, as well as potential in delivering benefits for care and health”, says Jan G. Smith.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • gothenburg life science

Regioner

  • Västra Götaland

Kontakter

Relaterat innehåll

  • Faster access to new and more effective medicines

    A long-term collaboration between AstraZeneca and Chalmers led to the founding of InSingulo in 2017. The core business is set up around the challenges of biophysics in drug discovery using single-molecule microscopy.
    The method developed by InSingulo provides improved sensitivity and low reagent consumption which is extremely valuable for new and challenging drug targets. This is especially tr

  • Specialist care with a holistic approach

    Atleva Specialistvård AB is a Swedish healthcare provider specialising in hand surgery, foot surgery and pain care, with focuson long-term non-malignant pain. Within the organisation there is also a clinic specialising in the prevention of ill health, acting as a health care partner to anyone wanting to make good health a main priority.
    Atleva Specialistvård was founded in 2008 by doctors who

  • Intelligent Simplicity is the way to go with dental implants

    Neoss is a pioneer in complete solutions for dental implants based on a single platform. With a single prosthetic platform, a simplicity of the system is guaranteed, which makes it easier for the dentists to learn, and which dramatically streamlines the work in the clinic. Neoss is now expanding further by strengthening their presence in USA and China.
    Although the Neoss implant system is base

  • Key2Compliance excels in QA Services

    Key2Compliance can help companies in the pharmaceutical, medical device and in vitro diagnostic industry to avoid the pitfalls that regulatory requirements may present. With a strong offer in Quality Assurance, Key2Compliance can help clients reach the next level – all the way from development to commercial phase.
    For individual innovators or SMEs, it can be difficult to keep track of the regul

  • The value of a Quality Target Product Profile in early development

    Clinical trials make up a substantial portion of the overall drug development costs and pharmaceutical companies are intensely focused on ensuring that the trial is well designed and developed. The development of the actual drug product, the Chemistry, Manufacturing and Controls (CMC) section of Investigational Medicinal Products Dossiers (IMPDs) or Investigational New Drug (IND) applications, is

  • The future of incontinence care is digital according to Essity

    Essity is a leader in digital health and facility management technologies such as incontinence change indicators, wound navigators and data-driven cleaning to transform healthcare, professional cleaning and people’s everyday lives.
    Under the global brand Tena, which has created products for incontinence care for over 60 years, the company has set out to challenge perceptions of an entire categ